As we age, the protective caps of our chromosomes shorten. This causes our cells to ‘age’ and become less healthy. When this shortening happens within our immune system cells, it can increase the risk of heart attacks and other heart problems.
There is a drug called TA-65MD which may help to make the protective caps longer and therefore healthier again.
The TACTIC trial aims to establish whether treatment with TA-65MD for one year can in fact increase the length of the protective caps and reduce the amount of aged cells in patients with heart disease.
Ninety patients with heart disease, who have had a heart attack will be recruited to the trial. They will be split into two groups. One group will be taking a placebo (dummy drug) and the other group will be taking TA-65MD.
The patients will not know which group they are in. All patients will have blood samples and echocardiograms taken before and after the trial in order to compare results.
Watch our short video about the trial
Prof Kim Spyridopoulos (CI), Dr David Austin (PI)[CL(STNT1]
Completed, no longer recruiting.
South Tees Hospitals NHS Foundation Trust